A patient with HPV-positive head and neck squamous cell carcinoma was dosed in a phase 1 clinical trial evaluating APR-1051.

DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) announced a key milestone in its ACESOT-1051 clinical trial, as the ...

HPV driven cancers, including HPV+ HNSCC, are characterized by defects in the DDR pathway, making them potentially susceptible to WEE1 inhibition. HPV+ cancers are those where the underlying cause is ...

Aprea Therapeutics (APRE) announced that a patient with HPV+ head and neck squamous cell carcinoma, HNSCC, has been dosed in the ongoing ...

Aprea Therapeutics has dosed a subject with human papillomavirus (HPV)-positive head and neck squamous cell carcinoma (HNSCC) ...

(RTTNews) - Aprea Therapeutics, Inc.(APRE), a clinical-stage biopharmaceutical company, Monday announced that it has dosed a patient with HPV+ Head and Neck Squamous Cell Carcinoma or HNSCC in its ...

However, if the cancer can halt replication long enough to repair the damage, it can come back and fight again. Enter DNA-damage gatekeeper WEE1. Targeting this kinase can prevent DNA repair in ...

orally available dual inhibitor of WEE1 and YES1 kinases, for the treatment of pancreatic cancer, small cell lung cancer, ovarian cancer, breast cancer, and colorectal cancer. Improved safety ...

WEE1 inhibition has emerged as a promising ... “Enrollment of the first patient with HPV+ head and neck cancer in the Phase 1 ACESOT-1051 trial is an important step and is in line with our ...